相关实验视频

Updated: Jun 26, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

在中发现了一种新型PI3Kδ抑制剂,其中包括3,5,7-Trihydroxychroman-4-one向扩散大B细胞淋巴瘤

Wenqing Jia1,2, Jingdian Liu1, Xianchao Cheng2

  • 1College of Chemistry and Chemical Engineering, Qilu Normal University, Jinan 250200, China.

International journal of molecular sciences
|October 26, 2024
PubMed
概括

西利比宁有效地抑制PI3Kδ,这是扩散性大B细胞淋巴瘤 (DLBCL) 的关键驱动因素. 这种天然化合物为DLBCL治疗提供了一个有希望的,新的治疗策略,可能会减少副作用.

关键词:
DLBCL DLBCL 是一个字母.在PI3Kδδ分子动力学分子动力学网络药理学 网络药理学虚拟选 虚拟选 虚拟选

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

相关概念视频

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...